Vertex Pharmaceuticals (NASDAQ: VRTX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
If you're looking for growth, these stocks could be just the ticket.
They've beaten the market before.
These stocks are great long-term picks.
There's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good.
These stocks should be even bigger winners than they already are when a new bull market takes hold.
These healthcare stocks show no signs of slowing down.
Vertex's encouraging mix of recurring revenue and growth make it a leader.
There is rarely a bad time to buy stocks with massive upside potential.
Valuation
Podcast Episodes
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
We examine three biotech companies' past performances and future outlooks.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Earnings Transcripts
VRTX earnings call for the period ending June 30, 2023.
VRTX earnings call for the period ending March 31, 2023.
VRTX earnings call for the period ending December 31, 2022.
VRTX earnings call for the period ending September 30, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.